Slow-growing melanomas lose structure, vary color with time

June 1, 2012
Slow-Growing melanomas lose structure, vary color with time
The diameter of most slow-growing melanomas changes very little over time, but the lesions can become more disorganized, less structured, and change or develop new colors, according to a study published in the June issue of the British Journal of Dermatology.

(HealthDay) -- The diameter of most slow-growing melanomas (SGMs) changes very little over time, but the lesions can become more disorganized, less structured, and change or develop new colors, according to a study published in the June issue of the British Journal of Dermatology.

Vitaly Terushkin, M.D., of Memorial Sloan-Kettering Cancer Center in New York City, and colleagues retrospectively assessed a dermoscopic image dataset of 92 SGMs from 15 pigmented lesion clinics that were sequentially followed for one year or more. Changes in global pattern, organization, color, structure, and were evaluated at baseline and follow-up.

The researchers found that, on follow-up, the dermoscopic pattern of the melanomas became more homogeneous and less reticular; the melanomas had more frequent disorganization of pattern; there was a reduction in the prominence of dermoscopic structure of pigmented network and a simultaneous increase in the prominence of areas with no structure; and they developed more melanoma-specific dermoscopic structures. Color changes included a decrease in light brown and increases in the prominence of dark brown and the frequency of new (red, white, grey, blue, and black). Seventy-five percent of grew by less than 2 mm or remained the same size; an increase in size correlated with the total number of colors and structures.

"Physicians should pay particular attention to melanocytic lesions that, over time, become more disorganized, reveal a loss of network in favor of structureless areas, develop a negative network, and exhibit new colors such as dark brown, black, grey, blue, red, and white; in addition, one should not rely solely on change in size," the authors write.

Explore further: Melanoma screening by physicians associated with finding more cancers than patient self-detection

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Melanoma screening by physicians associated with finding more cancers than patient self-detection

July 18, 2011
Physician-based screening for melanoma is associated with higher rates of physician-detected melanoma and detection of thinner melanoma, according to a report published Online First today by Archives of Dermatology, one of ...

Patients referred to dermatologists skin lesions evaluations also found to have other skin cancers

May 16, 2011
Among patients referred by non-dermatologists to dermatologists for evaluation of skin lesions suspected of being malignant, only apparently one-fifth were found to be cancerous, although dermatologists identified and biopsied ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.